Systemic sclerosis & Raynaud's
Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis
Authors' conclusion
GERD had no effect on survival in SSc or SSc-ILD. PPIs improved survival in patients with SSc-ILD.
Study context
- Population
- Patients with SSc and SSc-ILD from the German Network for Systemic Sclerosis (DNSS) database1,931 with SSc-ILD
- Participants
- 4,306 patients
- Exposure
- PPI use vs no PPI use; Gastroesophageal reflux disease (GERD) vs no GERD
- GERDn = 2,693
- Outcome
- OS and PFS (progression: decrease in % predicted FVC ≥10% or DLCO ≥15%, or death)
Methodological detailsregistry (DNSS database, 2003 onwards), Kaplan-Meier analysis
- Registry (DNSS database, 2003 onwards)
- Kaplan-Meier analysis
Main finding
As reported in the abstract
OS in SSc-ILD, PPI vs no PPI · 5 years
P < 0.0001
Observational data: associations, not effects.
Further findings
| Outcome | PPI | No PPI | P value |
|---|---|---|---|
| OS in SSc-ILD, PPI vs no PPI · 1 year | 98.4% (95% CI 97.6–99.3) · n = 760 | 90.8% (95% CI 87.9–93.8) · n = 290 | |
| PFS in SSc-ILD, PPI vs no PPI · 1 year | 95.9% (95% CI 94.6–97.3) · n = 745 | 86.4% (95% CI 82.9–90.1) · n = 278 | |
| PFS in SSc-ILD, PPI vs no PPI · 5 years | 66.8% (95% CI 63.0–70.8) · n = 286 | 45.9% (95% CI 39.6–53.2) · n = 69 | P < 0.0001 |
GERD prevalence and overall survival (OS)/progression-free survival (PFS), GERD vs without GERD
- GERD in SSc
- 2693/4306 (63%)
- GERD in SSc-ILD
- 1204/1931 (62%)
- GERD not associated with decreased OS or decreased PFS in either cohort
Original publication
Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis. Rheumatology (Oxford). Published 27 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →